华东医药：获VC005大陆独家许可，付5000万首付

Core Viewpoint - Huadong Medicine has secured exclusive commercialization rights for the oral formulation VC005 in mainland China through a partnership with Jiangsu Weikail [1] Group 1: Company Overview - Huadong Medicine's subsidiary, Huadong Medicine Hangzhou, will make an initial payment of 50 million RMB and may pay up to 180 million RMB in milestone payments related to registration [1] - VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor aimed at treating inflammatory and autoimmune diseases, currently in Phase III clinical trials for moderate to severe atopic dermatitis [1]